Fibulin‐2 and its association with fibrillin‐rich microfibrils in the papillary dermis of photoaged skin

SIR, Many thanks are due to Deirdre Buckley and Anthony Du Vivier for their extremely comprehensive and informative review of the use of topical contact sensitizers. I have been involved in a systematic review of randomized controlled trials for all local treatments for cutaneous warts; during our searches we discovered two randomized controlled trials of dinitrochlorobenzene (DNCB) which were subsequently included in our review. Neither trial was mentioned in the review by Buckley and Du Vivier and both are worthy of comment. The trials were small (80 patients in total) and of relatively low quality but they have the advantage of being properly randomized and hence less prone to bias. Data pooled from these trials showed cure in 32 of 40 (80%) with active treatment and 15 of 40 (38%) with placebo, odds ratio 6Æ67 (95% confidence interval 2Æ44–18Æ23), random effects model. There were no precise data concerning adverse effects in either of these trials but Rosado-Cancino et al. commented that six of their 20 participants treated with DNCB sensitized only after the second application of 2% DNCB to the warts. All of these patients subsequently experienced significant local irritation, with or without blistering, when they were treated with 1% DNCB. None withdrew from the study. In our review, cryotherapy, interestingly, fared slightly less well than simple topical treatments containing salicylic acid, with much more substantial evidence for the efficacy of the latter than the former. Two trials (involving a total of 320 participants) comparing these two treatments showed them to be only of equivalent efficacy, with cure rates of approximately 60–70%. Of all the treatments reviewed, DNCB came out with the highest odds ratio for cure of warts, albeit with rather wide confidence intervals because of the small numbers in these two trials. We thought it reasonable to conclude, however, that topical immunotherapy with sensitizers such as DNCB appears to be one of the more promising therapeutic avenues for refractory warts.

[1]  T. Krieg,et al.  Increased deposition of fibulin‐2 in solar elastosis and its colocalization with elastic fibres , 2001, The British journal of dermatology.

[2]  P. Steijlen,et al.  A case of Rombo syndrome , 2001, The British journal of dermatology.

[3]  R. Stern.  The risk of melanoma in association with long-term exposure to PUVA. , 2001, Journal of the American Academy of Dermatology.

[4]  J. Ring,et al.  Toxische epidermale Nekrolyse (Arzneimittel-induziertes Lyell-Syndrom) - Teil 1: Klinik und Differentialdiagnose¹ - , 2001 .

[5]  D. Heimbach,et al.  Toxic epidermal necrolysis (TEN) in elderly patients. , 2001, The Journal of burn care & rehabilitation.

[6]  G. Wasner,et al.  Clinical picture: nail changes secondary to docetaxel. , 2001, Lancet.

[7]  H. Chae,et al.  Peroxiredoxin is ubiquitously expressed in rat skin: isotype-specific expression in the epidermis and hair follicle. , 2000, The Journal of investigative dermatology.

[8]  A. Vanderkelen,et al.  Immunoregulatory Effector Cells in Drug-Induced Toxic Epidermal Necrolysis , 2000, The American Journal of dermatopathology.

[9]  M. de la Brassinne,et al.  Subungual abscess: a new ungual side‐effect related to docetaxel therapy , 2000, The British journal of dermatology.

[10]  V. Krčméry.  Systemic chlorellosis, an emerging infection in humans caused by algae. , 2000, International journal of antimicrobial agents.

[11]  Lawrence,et al.  The long‐term results of cartilage removal alone for the treatment of chondrodermatitis nodularis , 1999, The British journal of dermatology.

[12]  J. Polónia,et al.  Nail Changes Secondary to Docetaxel (Taxotere) , 1999, Dermatology.

[13]  C. Griffiths,et al.  Fibrillin-rich microfibrils are reduced in photoaged skin. Distribution at the dermal-epidermal junction. , 1999, The Journal of investigative dermatology.

[14]  G. Kao,et al.  Disseminated cutaneous protothecosis in an immunocompromised host: a case report and literature review. , 1999, Cutis.

[15]  T. Slaga,et al.  Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. , 1999, Journal of the National Cancer Institute.

[16]  P. Haslett,et al.  Thalidomide in toxic epidermal necrolysis , 1999, The Lancet.

[17]  C. Brun-Buisson,et al.  Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis , 1998, The Lancet.

[18]  C. Jacob,et al.  Nail bed dyschromia secondary to docetaxel therapy. , 1998, Archives of dermatology.

[19]  S. Rhee,et al.  Mammalian Peroxiredoxin Isoforms Can Reduce Hydrogen Peroxide Generated in Response to Growth Factors and Tumor Necrosis Factor-α* , 1998, The Journal of Biological Chemistry.

[20]  S. Rhee,et al.  Characterization of a Mammalian Peroxiredoxin That Contains One Conserved Cysteine* , 1998, The Journal of Biological Chemistry.

[21]  M. Binder,et al.  Onycholysis in patients treated with docetaxel. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  K. Jeang,et al.  Regulatory Role for a Novel Human Thioredoxin Peroxidase in NF-κB Activation* , 1997, The Journal of Biological Chemistry.

[23]  X. Pivot,et al.  Docetaxel chemotherapy induces transverse superficial loss of the nail plate. , 1997, Archives of dermatology.

[24]  N. Bräu,et al.  Cutaneous protothecosis in a patient with AIDS and a severe functional neutrophil defect: successful therapy with amphotericin B. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  D. Y. Sanders,et al.  Cutaneous protothecosis in association with the acquired immunodeficiency syndrome. , 1997, Southern medical journal.

[26]  M. Song,et al.  Docetaxel-induced subungual hemorrhage. , 1997, Dermatology.

[27]  Y. Chae,et al.  Successful treatment with fluconazole of protothecosis developing at the site of an intralesional corticosteroid injection , 1996, The British journal of dermatology.

[28]  J. Roujeau,et al.  Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis , 1996, The British journal of dermatology.

[29]  E. Koestenblatt,et al.  Cutaneous protothecosis and AIDS. , 1994, Journal of the American Academy of Dermatology.

[30]  J. Uitto,et al.  Enhanced elastin and fibrillin gene expression in chronically photodamaged skin. , 1994, The Journal of investigative dermatology.

[31]  G. Church,et al.  Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Stern,et al.  The carcinogenic risk of treatments for severe psoriasis , 1994, Cancer.

[33]  A. Vanderkelen,et al.  Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. , 1994, Archives of dermatology.

[34]  J. Ferguson,et al.  Narrow‐band (TL‐01) UVB air‐conditioned phototherapy for chronic severe adult atopic dermatitis , 1993, The British journal of dermatology.

[35]  L. Kaufman,et al.  Meningitis due to Prototheca wickerhamii in a patient with AIDS. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  G. M. Ridder,et al.  Age, sunlight, and facial skin: a histologic and quantitative study. , 1991, Journal of the American Academy of Dermatology.

[37]  C. Lawrence.  The treatment of chondrodermatitis nodularis with cartilage removal alone. , 1991, Archives of dermatology.

[38]  J. Hawk,et al.  The role of psoralen photochemotherapy (PUVA) in the treatment of severe atopic eczema in adolescents , 1988, The British journal of dermatology.

[39]  I. Penn,et al.  Cancers following cyclosporine therapy. , 1987, Transplantation proceedings.

[40]  M. Beck.  Treatment of chondrodermatitis nodularis helicis and conventional wisdom? , 1985, The British journal of dermatology.

[41]  J. Parsons.  Management of toxic epidermal necrolysis. , 1985, Cutis.

[42]  P. Suthipinittharm,et al.  Protothecosis: a report of two cases. , 1983, Mykosen.

[43]  P. Westermark,et al.  The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, basal cell carcinomas and peripheral vasodilation with cyanosis. , 1981, Acta dermato-venereologica.

[44]  R. Dobson,et al.  British Association of Dermatologists , 2014 .

[45]  T. R. Wade.  Chondrodermatitis nodularis chronica helicis. A review with emphasis on steroid therapy. , 1979, Cutis.

[46]  J. Parrish,et al.  Oral psoralen photochemotherapy of atopic eczema , 1978, The British journal of dermatology.

[47]  H. Sacks,et al.  Cutaneous protothecosis in a patient receiving immunosuppressive therapy. , 1976, Archives of dermatology.

[48]  R. Ross,et al.  Elastic Fiber , 2020, Definitions.

[49]  J. Gõmez Orbaneja,et al.  [Toxic epidermal necrolysis]. , 1967, Revista clinica espanola.

[50]  H. Spencer,et al.  A CASE OF HUMAN PROTOTHECOSIS. , 1964, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[51]  E. Davidson,et al.  Alterations in human dermal connective tissue with age and chronic sun damage. , 1962, The Journal of investigative dermatology.